Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $55.00 short put and a strike $50.00 long put offers a potential 21.65% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $55.00 by expiration. The full premium credit of $0.89 would be kept by the premium seller. The risk of $4.11 would be incurred if the stock dropped below the $50.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
U.S. Cross-Country Skier Kris Freeman Named to 2014 Olympic Team
Wed, 22 Jan 2014 17:45:00 GMT
PR Newswire – #T1DiabetesChamp and #Lilly #Diabetes spokesperson Kris Freeman @TeamFreeBirdXC named to #Sochi2014 @USOlympic cross-country ski team #Lilly #Diabetes and @LillyHealth celebrate @TeamFreeBirdXC Kris Freeman's naming to 4th @USOlympic team @TeamFreeBirdXC Kris Freeman doesn't let T1 #diabetes stop him from chasing #Olympic gold, named to 4th @USOlympic team When he travels to Sochi, Russia, in February, it will mark the fourth consecutive Winter Olympics for the top-ranked skier, a remarkable achievement for a man whose career nearly ended when he was diagnosed with type 1 diabetes at age 19.
Quality Of Evidence Used By FDA To Approve New Drugs Varies Widely
Tue, 21 Jan 2014 23:53:00 GMT
Forbes – The quality of clinical trial evidence that formed the basis of FDA approval for new drugs approved between 2005 and 2012 varied widely across indications, according to a study in the Journal of the American Medical Association. And the researchers say more post-marketing studies are needed.
Ex-‘King of Biotech' set to serve four-year term for fraud
Tue, 21 Jan 2014 18:09:28 GMT
Ex-‘King of Biotech' set to serve four-year term for fraud
Tue, 21 Jan 2014 18:09:14 GMT
Ex-‘King of Biotech' set to serve four-year term for fraud
Tue, 21 Jan 2014 18:09:14 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook